Mouse brain striatum neurons

Lonza Biologics Inc offers wide range of pharma products and services which includes moda-vip™ visual intelligence portalLonza Biologics Inc offers wide range of pharma products and services which includes moda-vip™ visual intelligence portal. It belongs to pharma & biotech, informatics moda...

Lonza Biologics Inc offers wide range of pharma products and services which includes moda™ qc micro product overviewLonza Biologics Inc offers wide range of pharma products and services which includes moda™ qc micro product overview. It belongs to pharma & biotech, informatics moda™ , paper...

Lonza Biologics Inc offers wide range of pharma products and services which includes moda™ version 3.1Lonza Biologics Inc offers wide range of pharma products and services which includes moda™ version 3.1. It belongs to pharma & biotech, informatics moda™ , paperless qc micro solution servi...

Lonza Biologics Inc offers wide range of pharma products and services which includes motor neuron progenitors. It belongs to pluripotent stem cells pluripotent stem cells and media services and products category. It includes cryopreserved human motor neuron progenitors. It cells are derived from human emb...

Lonza Biologics Inc offers wide range of pharma products and services which includes mouse brain hippocampal neurons. It belongs to primary and adult stem cells, animal cells & media, mouse neural cells & media services and products category. It is a major component of the brains of humans and other mamma...

Lonza Biologics Inc offers wide range of pharma products and services which includes mouse brain mixed astrocytes. It belongs to primary and adult stem cells, animal cells & media, mouse neural cells & media services and products category. Applications: transfection, electrophysiological properties, neur...

Lonza Biologics Inc offers wide range of pharma products and services which includes mouse embryonic fibroblasts. It belongs to primary and adult stem cells, animal cells & media, mouse embryonic fibroblasts services and products category. It is dissociated from CD-1 mouse embryos, expanded by culture and ...

Lonza Biologics Inc offers wide range of pharma products and services which includes multi purpose media. It belongs to upstream serum-free media and feed formulations services and products category. Contact us for more information.

Lonza Biologics Inc offers wide range of pharma products and services which includes mycoplasma detection & removal. It belongs to cell culture products category. It includes background on mycoplasma contamination, mycoalert™ plus mycoplasma detection kit, mycoalert™ mycoplasma detection kit, myc...

Lonza Biologics Inc offers wide range of pharma products and services which includes rat microglia. It belongs to primary and adult stem cells, animal cells & media, rat neural cells and media. It is is one of the glial cell types in the CNS. It is an important integral component of neuro-glial cell network.

Lonza Biologics Inc offers wide range of pharma products and services which includes renal cell growth medium. It belongs to primary and adult stem cells, human primary cells and media, renal cells (normal & diseased) & media services & products category. It is is formulated for the growth of renal mesangi...

Lonza Biologics Inc offers wide range of pharma products and services which includes retinal cells & medium. It includes clonetics™ human rpe cells, rtegm™ retinal pigment epithelial cell growth medium. Appplication: age related macular, degeneration, retinistis pigmentosa, gene expression, cel...

Follow along for live updates from the Content team as we bring you the latest from CPHI North America 2023 - from session talks, panel discussions, interviews, and more, there's a lot to discover with CPHI Online at the Pennsylvania Convention Center! 

Enabling a healthier world.

The offering will accelerate timelines for the development and manufacturing of molecules and disruptive technologies

Rapid and efficient development of drug candidates is increasingly important for pharmaceutical companies with accelerated timelines and funding constraints. However, many early drug candidates have poor oral absorption properties making it challenging to achieve target pharmacokinetic (PK) profiles. Without upfront knowledge of absorption risks and mitigation strategies, poor absorption can significantly impact preclinical and clinical study timelines and costs. Physiologically-based pharmacokinetic (PBPK) modeling software, such as the GastroPlus® platform from Simulations Plus, simulates dynamic physiological factors impacting oral performance. When coupled with in vitro measurements, PBPK modeling is effective in early development for 1) identifying absorption risks, 2) assessing the potential for solubility enhancing formulations such as salts, cocrystals, or amorphous solid dispersions to mitigate these risks, and 3) designing and optimizing preclinical and clinical studies with respect to dose, prandial state, or gastric pH modification to maximize the likelihood of achieving desired PK profiles. In this presentation, we will demonstrate how PBPK models combined with Lonza’s custom and off-the shelf in vitro tools and solubility enhancement expertise can be used to identify and mitigate absorption risks in early drug development, reducing the need for drug product reformulation or repeated preclinical or clinical studies. Key Learning Objectives: Learn how PBPK modeling can identify potential oral absorption risks and mitigation strategies (e.g. bioavailability enhancement) for early drug candidates. Learn how PBPK modeling coupled with in vitro testing can guide early selection of drug form and formulation to achieve clinical study goals. Gain insights into how key drug and formulation factors including solubility, permeability, and dissolution rate can impact absorption risks such as poor oral bioavailability, food-drug interactions, and pH-dependent DDI effects.

The expansion includes the installation of a pilot suite with a 50-L fermenter and automation upgrades to accelerate clinical and commercial projects

The companies will establish a Centre of Excellence focused on exosome manufacturing and characterization technologies